Literature DB >> 28261694

Impact of clinically significant portal hypertension on surgical outcomes for hepatocellular carcinoma in patients with compensated liver cirrhosis: a propensity score matching analysis.

Chul Woo Jang1, Hyung Jun Kwon2, Horyon Kong2, Heontak Ha1, Young Seok Han1, Jae Min Chun1, Sang Geol Kim2, Yun Jin Hwang2.   

Abstract

BACKGROUNDS/AIMS: The roles of portal hypertension (PHT) on the postoperative course after hepatectomy are still debated. The aim of this study was to evaluate surgical outcomes of hepatectomy in patients with PHT.
METHODS: Data from 152 cirrhotic patients who underwent hepatectomy for hepatocellular carcinoma (HCC) were collected retrospectively. Patients were divided into two groups according to the preoperative presence of PHT as follows: 44 patients with PHT and 108 without PHT. Propensity score matching (PSM) analysis was used to overcome selection biases.
RESULTS: There were no significant differences in morbidity (56.8% vs. 51.9%, p=0.578) and 90-days mortality (4.5% vs. 4.6%, p=0.982) between the two groups. Post-hepatectomy liver failure (PHLF) was not significantly different between the two groups (43.2% vs. 35.2%, p=0.356). Patients without PHT had a better 5-year disease-free survival than those with PHT, although the difference did not reach statistical significance (30.9% vs. 17.2%, p=0.081). Five-year overall survivals were not significantly different between the two groups (46.6% vs. 54.9%, p=0.724). Repeat analyses after PSM showed similar rates of morbidity (p=0.819), mortality (p=0.305), PHLF (p=0.648), disease-free survival (p=0.241), and overall survival (p=0.619). The presence of PHT was not associated with either short-term or long-term poor surgical outcomes.
CONCLUSIONS: Child-Pugh A and B patients with PHT have surgical outcomes similar to those without PHT. Hepatectomy can be safely performed and can also be considered as a potentially curative treatment in HCC patients with PHT.

Entities:  

Keywords:  Complication; Hepatectomy; Hepatocellular carcinoma; Portal hypertension; Prognosis

Year:  2016        PMID: 28261694      PMCID: PMC5325151          DOI: 10.14701/ahbps.2016.20.4.159

Source DB:  PubMed          Journal:  Ann Hepatobiliary Pancreat Surg        ISSN: 2508-5859


  19 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

3.  Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Authors:  J M Llovet; J Fuster; J Bruix
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

4.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).

Authors:  Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

5.  Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value.

Authors:  G L Grazi; G Ercolani; F Pierangeli; M Del Gaudio; M Cescon; A Cavallari; A Mazziotti
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

Authors:  J Bruix; A Castells; J Bosch; F Feu; J Fuster; J C Garcia-Pagan; J Visa; C Bru; J Rodés
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

8.  One thousand fifty-six hepatectomies without mortality in 8 years.

Authors:  Hiroshi Imamura; Yasuji Seyama; Norihiro Kokudo; Atsushi Maema; Yasuhiko Sugawara; Keiji Sano; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2003-11

9.  Intraoperative portal venous pressure and long-term outcome after curative resection for hepatocellular carcinoma.

Authors:  M Hidaka; M Takatsuki; A Soyama; T Tanaka; I Muraoka; T Hara; T Kuroki; T Kanematsu; S Eguchi
Journal:  Br J Surg       Date:  2012-09       Impact factor: 6.939

10.  Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis.

Authors:  Andrea Lisotti; Francesco Azzaroli; Federica Buonfiglioli; Marco Montagnani; Paolo Cecinato; Laura Turco; Claudio Calvanese; Patrizia Simoni; Massimo Guardigli; Rosario Arena; Alessandro Cucchetti; Antonio Colecchia; Davide Festi; Rita Golfieri; Giuseppe Mazzella
Journal:  Hepatology       Date:  2013-12-20       Impact factor: 17.425

View more
  2 in total

1.  Predictive power of splenic thickness for post-hepatectomy liver failure in HBV-associated hepatocellular carcinoma patients.

Authors:  Xiang Chen; Heng Zou; Li Xiong; Sheng-Fu Huang; Xiong-Ying Miao; Yu Wen
Journal:  World J Surg Oncol       Date:  2017-12-04       Impact factor: 2.754

2.  The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients.

Authors:  Anli Yang; Weikai Xiao; Dong Chen; Xiaoli Wei; Shanzhou Huang; Ye Lin; Chuanzhao Zhang; Jianwei Lin; Feiwen Deng; Chenglin Wu; Xiaoshun He
Journal:  Cancer Med       Date:  2018-11-14       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.